Interview with Lee Rodne, CEO of Admedus

Admedus has had an interesting couple of months including the completion of a successful capital raising. The company has three business divisions, however, in this interview we focus specifically on the tissue regenerative medicines business. The lead product in this business is called Cardiocell and we ask Lee to share some more insights into this part of the Admedus business.


1 topic

1 stock mentioned

Scott Power
Senior Analyst
Morgans

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

trending on livewire
Get the best of Livewire by signing up to our popular daily newsletter